Biotest AG

  • WKN: 522723
  • ISIN: DE0005227235
  • Land: Deutschland

Nachricht vom 15.09.2021 | 07:00

Biotest AG: Biotest announces the new Renate & Hans Schleussner Award for scientific research

DGAP-News: Biotest AG / Key word(s): Miscellaneous
15.09.2021 / 07:00
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest announces the new Renate & Hans Schleussner Award for scientific research

  • Award's aim is promotion of innovative research in the field of therapies with (hyper-) immunoglobulins
  • In memory of the Schleussner family who founded Biotest, the new research award will be named the Renate & Hans Schleussner Award
  • € 50,000 will be awarded for a preclinical or clinical project


Dreieich, 15 September 2021. Biotest announced today that a new scientific award, the Renate & Hans Schleussner Award, which will be available and open for application from now on. The daughter from Renate & Hans, Cathrin Schleussner was a member of the Supervisory Board of "Biotest AG" since 2001 and held the position of Deputy Chairman from 2004 until the takeover by the Chinese "Creat Group" in 2018.

Immunoglobulins are a major component of the immune system. They are a potent natural tool to counteract viral and bacterial infections.

Scientists or clinicians with innovative ideas relevant to the prevention or treatment of viral infections with (hyper-) immunoglobulins are invited to submit their application. Projects should be related to pathology or management of the disease. Applicants must submit an original research contribution to basic or clinical research. Applications are encouraged from both individuals and teams conducting research at hospitals, universities or independent institutions.
Submissions will be evaluated by Biotest and an independent expert jury consisting of the following members: Prof. Martina Sester (Germany), Prof. Emanuele Cozzi (Italy), Prof. Stephen Jolles (U.K.), Prof. Srini Kaveri (France).

Deadline for the submission of a first project concept is January 31st, 2022. Selected awardees will be invited to prepare a full project proposal. Details on how to apply for the award can be found at:
https://www.biotest.com/de/en/company/corporate_social_responsibilit/renate--hans-schleussner-awar.cfm

 

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.



15.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Deutsche Wohnen SE: Mitteilung an die Gläubiger der Deutsche Wohnen SE Wandelschuldverschreibung über 800 Mio. EUR mit Fälligkeit 2024 (ISIN DE000A2BPB84)

14. September 2021, 19:45

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

16. September 2021